Ramucirumab with paclitaxel or FOLFIRI as second-line treatment in docetaxel-pre-treated patients with metastatic gastric cancer in real-world setting

Introduction. Ramucirumab (R) with paclitaxel (PTX) is a global standard for second-line (2L) therapy in advanced gastroesophageal adenocarcinoma (GEA). More and more patients (pts) get treated with taxanes in the perioperative or 1st line metastatic setting. For those pts the benefit of a combinati...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	N. S. Besova, Т. А. Titova, А. А. Tryakin, Е. V. Artamonova, Е. S. Obarevich, D. L. Stroyakovskiy, О. Е. Kalinin, I. S. Stilidi
Aineistotyyppi:	Artigo
Kieli:	Russo
Julkaistu:	Remedium Group LLC 2021-06-01
Sarja:	Медицинский совет
Aiheet:	ramucirumab disseminated gastric cancer irinotecan folfiri paclitaxel docetaxel second line therapy
Linkit:	https://www.med-sovet.pro/jour/article/view/6212
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!